A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys.


Journal

Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627

Informations de publication

Date de publication:
26 Jan 2021
Historique:
received: 13 10 2020
accepted: 08 01 2021
entrez: 27 1 2021
pubmed: 28 1 2021
medline: 30 10 2021
Statut: epublish

Résumé

It has been demonstrated that luteal phase support (LPS) is crucial in filling the gap between the disappearance of exogenously administered hCG for ovulation triggering and the initiation of secretion of endogenous hCG from the implanting conceptus. LPS has a pivotal role of in establishing and maintaining in vitro fertilization (IVF) pregnancies. Over the last decade, a plethora of studies bringing new information on many aspects of LPS have been published. Due to lack of consent between researchers and a dearth of robust evidence-based guidelines, we wanted to make the leap from the bench to the bedside, what are the common LPS practices in fresh IVF cycles compared to current evidence and guidelines? How has expert opinion changed over 10 years in light of recent literature? Over a decade (2009-2019), we conducted 4 web-based surveys on a large IVF-specialist website on common LPS practices and controversies. The self-report, multiple-choice surveys quantified results by annual IVF cycles. On average, 303 IVF units responded to each survey, representing, on average, 231,000 annual IVF cycles. Most respondents in 2019 initiated LPS on the day of, or the day after egg collection (48.7 % and 36.3 %, respectively). In 2018, 72 % of respondents administered LPS for 8-10 gestational weeks, while in 2019, 65 % continued LPS until 10-12 weeks. Vaginal progesterone is the predominant delivery route; its utilization rose from 64 % of cycles in 2009 to 74.1 % in 2019. Oral P use has remained negligible; a slight increase to 2.9 % in 2019 likely reflects dydrogesterone's introduction into practice. E2 and GnRH agonists are rarely used for LPS, as is hCG alone, limited by its associated risk of ovarian hyperstimulation syndrome (OHSS). Our Assisted reproductive technology (ART)-community survey series gave us insights into physician views on using progesterone for LPS. Despite extensive research and numerous publications, evidence quality and recommendation levels are surprisingly low for most topics. Clinical guidelines use mostly low-quality evidence. There is no single accepted LPS protocol. Our study highlights the gaps between science and practice and the need for further LPS research, with an emphasis on treatment individualization.

Sections du résumé

BACKGROUND BACKGROUND
It has been demonstrated that luteal phase support (LPS) is crucial in filling the gap between the disappearance of exogenously administered hCG for ovulation triggering and the initiation of secretion of endogenous hCG from the implanting conceptus. LPS has a pivotal role of in establishing and maintaining in vitro fertilization (IVF) pregnancies. Over the last decade, a plethora of studies bringing new information on many aspects of LPS have been published. Due to lack of consent between researchers and a dearth of robust evidence-based guidelines, we wanted to make the leap from the bench to the bedside, what are the common LPS practices in fresh IVF cycles compared to current evidence and guidelines? How has expert opinion changed over 10 years in light of recent literature?
METHODS METHODS
Over a decade (2009-2019), we conducted 4 web-based surveys on a large IVF-specialist website on common LPS practices and controversies. The self-report, multiple-choice surveys quantified results by annual IVF cycles.
RESULTS RESULTS
On average, 303 IVF units responded to each survey, representing, on average, 231,000 annual IVF cycles. Most respondents in 2019 initiated LPS on the day of, or the day after egg collection (48.7 % and 36.3 %, respectively). In 2018, 72 % of respondents administered LPS for 8-10 gestational weeks, while in 2019, 65 % continued LPS until 10-12 weeks. Vaginal progesterone is the predominant delivery route; its utilization rose from 64 % of cycles in 2009 to 74.1 % in 2019. Oral P use has remained negligible; a slight increase to 2.9 % in 2019 likely reflects dydrogesterone's introduction into practice. E2 and GnRH agonists are rarely used for LPS, as is hCG alone, limited by its associated risk of ovarian hyperstimulation syndrome (OHSS).
CONCLUSIONS CONCLUSIONS
Our Assisted reproductive technology (ART)-community survey series gave us insights into physician views on using progesterone for LPS. Despite extensive research and numerous publications, evidence quality and recommendation levels are surprisingly low for most topics. Clinical guidelines use mostly low-quality evidence. There is no single accepted LPS protocol. Our study highlights the gaps between science and practice and the need for further LPS research, with an emphasis on treatment individualization.

Identifiants

pubmed: 33499875
doi: 10.1186/s12958-021-00696-2
pii: 10.1186/s12958-021-00696-2
pmc: PMC7836509
doi:

Substances chimiques

Progesterone 4G7DS2Q64Y

Types de publication

Historical Article Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15

Références

Fertil Steril. 2005 May;83(5):1372-6
pubmed: 15866571
Reprod Biomed Online. 2018 Jun;36(6):630-645
pubmed: 29550390
Gynecol Endocrinol. 2014;30(12):902-8
pubmed: 25268567
Hum Reprod. 1990 Jul;5(5):537-43
pubmed: 2394784
Fertil Steril. 2018 May;109(5):749-755
pubmed: 29778367
Fertil Steril. 2010 Aug;94(3):946-51
pubmed: 19523613
Gynecol Endocrinol. 2020 May;36(5):389-397
pubmed: 32054365
Trends Endocrinol Metab. 2003 Jul;14(5):236-42
pubmed: 12826330
Hum Reprod. 2008 Apr;23(4):857-62
pubmed: 18270182
Trials. 2012 Jul 26;13:118
pubmed: 22834768
JBRA Assist Reprod. 2018 Jun 01;22(2):148-156
pubmed: 29488367
N Engl J Med. 2019 Apr 4;380(14):1347-1358
pubmed: 30943338
J Assist Reprod Genet. 2003 Dec;20(12):517-20
pubmed: 15035552
Hum Reprod. 2006 Jul;21(7):1894-900
pubmed: 16556673
Fertil Steril. 2001 Jun;75(6):1136-40
pubmed: 11384639
Fertil Steril. 1999 Jan;71(1):11-4
pubmed: 9935109
Hum Reprod. 1999 Aug;14(8):1944-8
pubmed: 10438404
Hum Reprod Update. 2007 Nov-Dec;13(6):581-90
pubmed: 17626114
PLoS One. 2016 Mar 18;11(3):e0151388
pubmed: 26991890
J Assist Reprod Genet. 2019 May;36(5):1013-1021
pubmed: 30788661
Hum Reprod. 2006 Apr;21(4):905-8
pubmed: 16373409
Hum Reprod. 1992 Jun;7 Suppl 1:1-5
pubmed: 1332985
Fertil Steril. 2000 Apr;73(4):761-6
pubmed: 10731538
Int J Fertil. 1989 May-Jun;34(3):188-93
pubmed: 2567713
Gynecol Endocrinol. 2017 Aug;33(8):602-606
pubmed: 28277886
Hum Fertil (Camb). 2016 Jun;19(2):142-9
pubmed: 27434094
Cochrane Database Syst Rev. 2015 Jul 07;(7):CD009154
pubmed: 26148507
Reprod Biomed Online. 2018 Apr;36(4):427-434
pubmed: 29398418
Hum Fertil (Camb). 2015 Mar;18(1):43-7
pubmed: 25116191
Fertil Steril. 2018 Jan;109(1):97-103
pubmed: 29175065
Reprod Biol Endocrinol. 2012 Dec 13;10:107
pubmed: 23237065
Fertil Steril. 2017 May;107(5):1092-1097
pubmed: 28433368
Fertil Steril. 1999 Apr;71(4):614-8
pubmed: 10202868
Gynecol Endocrinol. 1996 Aug;10(4):273-6
pubmed: 8908528
Hum Reprod. 2002 Feb;17(2):357-61
pubmed: 11821278
Fertil Steril. 2012 Oct;98(4):858-62
pubmed: 22749223
Reprod Biomed Online. 2012 Aug;25(2):139-45
pubmed: 22683150
Fertil Steril. 2017 Jan;107(1):130-135.e1
pubmed: 28228316
Reprod Biomed Online. 2020 Jan;40(1):143-150
pubmed: 31864902
Reprod Biomed Online. 2017 Dec;35(6):693-700
pubmed: 28988928
Gynecol Endocrinol. 2013 Jul;29(7):700-3
pubmed: 23772781
Fertil Steril. 2001 Dec;76(6):1140-3
pubmed: 11730741
Obstet Gynecol. 2000 Mar;95(3):403-6
pubmed: 10711552
Hum Reprod. 2011 May;26(5):1020-4
pubmed: 21296803
Gynecol Endocrinol. 2019 May;35(5):368-369
pubmed: 30614333
Eur J Obstet Gynecol Reprod Biol. 2011 Feb;154(2):172-6
pubmed: 21067858
Hum Reprod. 1996 May;11(5):943-9
pubmed: 8671368
Presse Med. 1990 Mar 24;19(11):527
pubmed: 2138757
Hum Reprod. 1997 May;12(5):1073-9
pubmed: 9194669
Hum Reprod. 2018 Dec 1;33(12):2212-2221
pubmed: 30304457
Fertil Steril. 1994 Jun;61(6):1068-76
pubmed: 8194619
Reprod Biomed Online. 2014 May;28(5):552-9
pubmed: 24656557
Fertil Steril. 2000 Mar;73(3):516-21
pubmed: 10689005
Hum Reprod. 2006 Oct;21(10):2628-32
pubmed: 16857887

Auteurs

Gon Shoham (G)

Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, P.O.B. 39040, 69978, Tel Aviv, Israel. gonshoha@tauex.tau.ac.il.

Milton Leong (M)

The IVF Clinic, 13/F Central Tower, 28 Queens Road Central, Hong Kong, China.

Ariel Weissman (A)

Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, P.O.B. 39040, 69978, Tel Aviv, Israel.
IVF Unit, Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, 62 Halochamim Street, 5822012, Holon, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH